CME/CE Podcast: Streamlined Strategies for Managing Tardive Dyskinesia

The NACE Clinical Highlights Show

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/streamlined-strategies-for-managing-tardive-dyskinesia-9842
Summary
Tardive dyskinesia (TD) is a debilitating movement disorder that manifests as involuntary, repetitive movements, often of the face, tongue, and extremities. These symptoms frequently result from prolonged use of antipsychotic medications, particularly in patients being treated for schizophrenia, bipolar disorder, or major depressive disorder. Accurate and routine assessment of TD is critical to prevent symptom progression and improve patient outcomes. The Abnormal Involuntary Movement Scale (AIMS) is a widely accepted, gold-standard tool used to detect and measure the severity of involuntary movements. AIMS enables clinicians to detect involuntary movements early and track the disorder's progression, facilitating timely intervention and individualized treatment plans.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic delve into the complexities of diagnosing and managing tardive dyskinesia (TD), emphasizing evidence-based strategies to improve patient outcomes. They discuss the importance of using the Abnormal Involuntary Movement Scale (AIMS), a standardized and validated tool, for regular TD assessment. AIMS enables clinicians to detect involuntary movements early and track the disorder's progression, facilitating timely intervention and individualized treatment plans.

Learning Objective
At the conclusion of this activity, participants should be better able to:

• Explore strategies to simplify management and optimally improve outcomes for patients with TD

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [e-mail].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Neurocrine Biosciences.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.